(S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate | 1251826-87-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate
• 英文别名: methyl (2S)-2-methyl-3-trimethylsilyloxypropanoate
• CAS: 1251826-87-5
• 化学式: C₈H₁₈O₃Si
• 分子量: 190.315
• InChiKey: AKBKCYYTOZJOAH-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.65
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate 、 在 (S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate 作用下， 以45.9的产率得到
  参考文献：
  名称：

  Vitamin D Receptor Agonists and Uses Thereof

  摘要：

  本发明公开了一种式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和a如本文所定义，或其药学上可接受的盐。本发明还公开了一种包括式（I）的化合物或其盐的制药组合物，以及一种治疗需要调节维生素D受体的疾病的方法，例如骨疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫紊乱、左心室肥厚、增生性疾病、蛋白尿、肾脏疾病和血栓形成等疾病。

  公开号：

  US20120115824A1
• 作为产物：
  描述：

  (S)-(+)-3-羟基异丁酸甲酯 以65.1的产率得到(S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate
  参考文献：
  名称：

  Vitamin D Receptor Agonists and Uses Thereof

  摘要：

  本发明公开了一种式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和a如本文所定义，或其药学上可接受的盐。本发明还公开了一种包括式（I）的化合物或其盐的制药组合物，以及一种治疗需要调节维生素D受体的疾病的方法，例如骨疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫紊乱、左心室肥厚、增生性疾病、蛋白尿、肾脏疾病和血栓形成等疾病。

  公开号：

  US20120115824A1
• 作为试剂：
  描述：

  (S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate 、 在 (S)-methyl 2-methyl-3-(trimethylsilyloxy)propanoate 作用下， 以45.9的产率得到
  参考文献：
  名称：

  Vitamin D Receptor Agonists and Uses Thereof

  摘要：

  本发明公开了一种式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和a如本文所定义，或其药学上可接受的盐。本发明还公开了一种包括式（I）的化合物或其盐的制药组合物，以及一种治疗需要调节维生素D受体的疾病的方法，例如骨疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫紊乱、左心室肥厚、增生性疾病、蛋白尿、肾脏疾病和血栓形成等疾病。

  公开号：

  US20120115824A1

文献信息

• Singly Hydrogen Bonded Supramolecular Ligands for Highly Selective Rhodium-Catalyzed Hydrogenation Reactions
  作者：Pierre-Alain R. Breuil、Frederic W. Patureau、Joost N. H. Reek

  DOI：10.1002/anie.200806177

  日期：2009.3.9

  catalysts! A single hydrogen bond between ligands coordinated to a rhodium center is critical for the formation of pure supramolecular catalysts for asymmetric hydrogenation reactions. The ester group of the amidite ligand (see scheme) also forms a hydrogen bond with the coordinated substrate. Use of the heterocomplex afforded the highest enantioselectivity reported to date for the hydrogenation of several

  H键是催化剂！与铑中心配位的配体之间的单个氢键对于形成用于不对称氢化反应的纯超分子催化剂至关重要。酰胺基配体的酯基（参见方案）也与配位的底物形成氢键。杂合物的使用提供了迄今为止报道的几种酯底物氢化的最高对映选择性。
• [EN] VITAMIN D RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE LA VITAMINE D ET UTILISATIONS CORRESPONDANTES
  申请人：VIDASYM LLC

  公开号：WO2010120698A1

  公开（公告）日：2010-10-21

  Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

  揭示的是化合物Formula (I)，其中R1、R2、R3、R4、R5、R6、X和a在此处定义，或其药用可接受盐。还揭示了一种包含Formula (I)的化合物或其盐的制药组合物，以及一种治疗受益于调节维生素D受体的疾病的方法，如骨骼疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫障碍、左心室肥厚、增殖性疾病、蛋白尿、肾脏疾病和血栓形成。
• Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects
  作者：Barbara Chen、Megumi Kawai、J. Ruth Wu-Wong

  DOI：10.1016/j.bmcl.2013.08.076

  日期：2013.11

  We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3 alpha S,7 alpha S)-1-((R)-1-((S)-3-hydroxy-2,3-dimethylbutoxy)ethyl)-7 alpha-methyldihydro-1H-inden-4(2H,5H,6H,7H,7 alpha H)-ylidene) ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation of a-ring phenylphosphine oxide 11, followed by Wittig-Horner coupling of 11 with the protected 25-hydroxy Grundmann's ketone 22 generated the precursor 12. Deprotection of the TBDMS groups of 12 produced the target compound VS-105. The biological profiles of VS-105 were evaluated using in vitro assays (VDR receptor binding, VDR reporter gene and HL-60 differentiation) in comparison to calcitriol (the endogenous hormone) or paricalcitol. Furthermore, the PTH suppressing potency and hypercalcemic side effects of VS-105 were evaluated in the 5/6 nephrectomized uremic rats in comparison to paricalcitol. Combining various changes at 20-epi, 22-oxa, 24-methyl, and 2-methylene yielded VS-105 that not only is highly potent in inducing functional responses in vitro, but also effectively suppresses PTH in a dose range that does not affect serum calcium in the 5/6 nephrectomized uremic rats. (C) 2013 Elsevier Ltd. All rights reserved.
• Vitamin D Receptor Agonists and Uses Thereof
  申请人：Kawai Megumi

  公开号：US20120115824A1

  公开（公告）日：2012-05-10

  Disclosed is a compound of Formula (I) in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt thereof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

  本发明公开了一种式（I）的化合物，其中R1、R2、R3、R4、R5、R6、X和a如本文所定义，或其药学上可接受的盐。本发明还公开了一种包括式（I）的化合物或其盐的制药组合物，以及一种治疗需要调节维生素D受体的疾病的方法，例如骨疾病、心血管疾病、与肾脏疾病相关的心血管并发症、内皮功能障碍、甲状旁腺功能亢进、低钙血症、免疫紊乱、左心室肥厚、增生性疾病、蛋白尿、肾脏疾病和血栓形成等疾病。